Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
 PI3K and mTOR protein kinase inhibitor GSK 2126458, 2 mg  

PI3K and mTOR protein kinase inhibitor GSK 2126458, 2 mg

2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide

GSK 2126458 is a highly potent and orally bioavailable inhibitor of PI3K and mTOR in vitro and in vivo.
Synonyms: Omipalisib

More details

PKI-GSK212-002

Availability: within 3 days

136,00 €

Background: GSK 2126458 / Omipalisib is a highly potent and orally bioavailable inhibitor of PI3K and mTOR in vitro and in vivo; Ki values to be 0.019, 0.13, 0.024 and 0.06 nM for p110 α, β, δ and γ isoforms and 0.18 and 0.3 nM for mTORC1 and mTORC2 respectively.

Chemical formula: C25H17F2N5O3S
Molecular weight: 505.50 g/mol
Purity: 99 %
Appearance: Off-white solid
Solubility: Soluble in DMSO
CAS Number: 1086062-66-9

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

SD Knight et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med. Chem. Lett. 2010, 1(1), 39–43.
 
E Leung et al. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol. Ther. 2011, 11(11), 938-946.

The following products could also be interesting for you: